Hepatitis B Mapping Project
The Hepatitis B Mapping Project is a joint initiative of ASHM and the Victorian Infectious Diseases Reference Laboratory (VIDRL). The project aims to produce a comprehensive understanding of chronic hepatitis B (CHB) in Australia using data to geographically map both disease burden and estimates of chronic hepatitis B (CHB) diagnosis, monitoring and treatment uptake. This will help to prioritise and evaluate health interventions, improve local service delivery and address the needs of local priority populations.
Download the first Hepatitis B Mapping Project National Report
Hepatitis B Mapping Project: Estimates of chronic hepatitis B prevalence and
cultural and linguistic diversity by Medicare Local, 2011 National Report (PDF 900kB): Focusing on baseline Medicare Local prevalence estimates and demographic and linguistic information.
New National Report Coming Soon
A second national report for the hepatitis B mapping project is due to be released in November 2014. The report will use national datasets to indicate the current level of diagnosis (notifications), monitoring (viral load testing) and treatment (antiviral uptake), as well as vaccination and outcomes of infection (local incidence of liver cancer); providing a benchmark against which progress in achieving these priorities can be assessed at the national, jurisdictional, and local levels.
Why do we need to map the extent of hepatitis B?
Around 218,000 people were estimated to be living with CHB in Australia in 2011, approximately 1.0% of the population. In Australia, people born overseas (particularly from Asia, the Pacific and Africa) and Aboriginal and Torres Strait Islander people are disproportionately affected by CHB.
Due to these epidemiological determinants, CHB is not evenly distributed geographically in Australia with wide variation by area.
Enhancing access to treatment and care, a priority action in the National Hepatitis B Strategy, relies on people receiving information, being diagnosed, and able to access culturally appropriate and safe healthcare.
What is being mapped?
The project uses a range of indicators to estimate the burden of disease and also the uptake of treatment and care, including census demographic data, surveillance notifications, hepatocellular carcinoma (HCC) incidence and prescriptions for CHB antivirals.
The demographic approaches used allow the most affected groups (by country of birth or Aboriginal and Torres Strait Islander status) to be identified in particular Medicare Locals. The impact of public health and clinical service interventions to increase access to diagnosis and treatment will also be evaluated at a population level over time.
How can the project outputs be used?
The project is geographically mapping the burden of disease to identify priority Medicare Locals with a significant burden of CHB and outcomes including liver cancer and to help inform appropriate responses to suit the needs of the affected population in those areas.
As the priority populations affected by CHB in Australia are subject to broader health disparities, the project will allow for awareness and intervention campaigns to be targeted in the most direct and appropriate ways.
Who is behind the Hepatitis B Mapping Project?
ASHM and VIDRL are working in partnership to produce a comprehensive understanding of the epidemiology of hepatitis B in Australia. The Hepatitis B Mapping Project commenced in 2012 and is funded by the Australian Department of Health.